Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Public ClinicalTrials.gov record NCT06456346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.
Study identification
- NCT ID
- NCT06456346
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Interventions
- Bomedemstat Drug
- Hydroxyurea Drug
- Bomedemstat placebo Drug
- Hydroxyurea placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 16, 2024 (Actual)
- Primary completion
- Sep 28, 2027 (Estimated)
- Completion
- Mar 24, 2028 (Estimated)
- Last update posted
- Aug 27, 2026
2024 – 2028
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palo Verde Cancer Specialists ( Site 0052) | Glendale | Arizona | 85304 | — |
| Los Angeles Cancer Network ( Site 0025) | Glendale | California | 91206 | — |
| Stanford Cancer Center ( Site 0024) | Palo Alto | California | 94304 | — |
| Exempla Lutheran Medical Center ( Site 0014) | Golden | Colorado | 80401 | — |
| Yale University School of Medicine ( Site 0051) | New Haven | Connecticut | 06510 | — |
| Parkview Research Center at Parkview Regional Medical Center ( Site 0006) | Fort Wayne | Indiana | 46845 | — |
| University of Michigan ( Site 0003) | Ann Arbor | Michigan | 48109 | — |
| Optum Care Cancer Center ( Site 0053) | Las Vegas | Nevada | 89102 | — |
| Levine Cancer Institute ( Site 0009) | Charlotte | North Carolina | 28204 | — |
| Duke University Health System (DUHS) ( Site 0012) | Durham | North Carolina | 27710 | — |
| Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 0013) | Winston-Salem | North Carolina | 27157 | — |
| The Ohio State University Wexner Medical Center ( Site 0028) | Columbus | Ohio | 43210 | — |
| Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8005) | Eugene | Oregon | 97401 | — |
| Oregon Health & Science University ( Site 0018) | Portland | Oregon | 97239 | — |
| TriStar Bone Marrow ( Site 7000) | Nashville | Tennessee | 37203 | — |
| Texas Oncology - West Texas ( Site 8003) | Amarillo | Texas | 79124 | — |
| Texas Oncology - DFW ( Site 8006) | Dallas | Texas | 75246 | — |
| University of Texas MD Anderson Cancer Center ( Site 0026) | Houston | Texas | 77030 | — |
| University of Texas Health Science Center at San Antonio ( Site 0021) | San Antonio | Texas | 78229 | — |
| Texas Oncology - Gulf Coast ( Site 8008) | Webster | Texas | 77598 | — |
| University of Virginia ( Site 0020) | Charlottesville | Virginia | 22908 | — |
| VCU Health Adult Outpatient Pavillion ( Site 0008) | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 149 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06456346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06456346 live on ClinicalTrials.gov.